Advantages of long-term management the metabolic health in patients with obesity and early disorders of carbohydrate metabolism

• Olga P. P'yanykh
• Dinara G. Gusenbekova
• Alexander S. Ametov

Abstract

The current task of modern endocrinology is still to find the optimal therapeutic approach that increases the effectiveness of managing the metabolic health in patients with obesity and early disorders of carbohydrate metabolism. Monotherapy with drugs registered in Russia for the treatment of obesity in patients with impaired fasting glycemia, impaired glucose tolerance, does not always lead to the achievement of targets for glycemia and other markers of metabolic status due to severe insulin resistance, endocrine activity of visceral adipose tissue that produces Pro-inflammatory adipokines, and eating disorders. In this connection, there is a need to intensify therapy with the use of two drugs, which often leads to a decrease in patients' compliance. Creating fixed combinations that act on various pathogenetic links solves the problem of achieving the therapeutic goal and improves the patient's commitment to long-term treatment.

The article presents the results of an observational study demonstrating the benefits of therapy with a fixed combination of Sibutramine and Metformin for 12 months in achieving metabolic health. It displays not only the high effectiveness of the drug in weight loss, but also a reduction in lipotoxicity, normalization of carbohydrate and lipid metabolism, a decrease in leptin and postprandial ghrelin, in most patients, the problem of eating disorders was solved. By the end of the study, there was a statistically significant improvement in the quality of life of the examined patients.

Keywords:obesity, prediabetes, metabolic health, metformin, sibutramine, Reduxine® Forte

References

1. World Health Organization Media Centre. Obesity and overweight. Fact sheet No. 311. Geneva: World Health Organization, 2013.

2. Romantsova T.I., Ostrovskaya E.V. Metabolically healthy obesity: definitions, protective factors, and clinical significance. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2015; (1): 75-86. (in Russian)

3. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and metaanalysis. Ann Intern Med. 2013; 159 (11): 758-69.

4. Shlyakhto E.V., Nedogoda S.V., Konradi A.O. National clinical recommendations: diagnostics, treatment, prevention of obesity and associated diseases. Saint Petersburg, 2017: 164 p. (in Russian)

5. Stefan N., Haring H.U., Hu F.B., Schulze M.B. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013; 1 (2): 152-62.

6. Rey-Lopez J.P., de Rezende L.F., Pastor-Valero M., Tess B.H. The prevalence of metabolically healthy obesity: a systematic review and critical evaluation of the definitions used. Obes Rev. 2014; 15 (10): 781-90.

7. Bardymova T.P., Berezina M.V., Batunova E.V., Miroshnichenko I.A. Metabolic features of obese patients. Meditsinskiy sovet [Medical Council]. 2017; (20): 157-9. URL: https://doi.org/10.21518/2079-701X-2017-20-157-159 (in Russian)

8. Dalantayeva N.S., Egorova N.S., Dzeranova N.S. Central mechanisms regulating energy exchange and sibutramine. Ozhirenie i metabolism [Obesity and Metabolism]. 2012; (3): 33-6. (in Russian)

9. Korneeva E.V. The role of ghrelin and leptin in the regulation of body weight in patients with metabolic syndrome. Vestnik novykh meditsinskikh tekhnologiy [Bulletin of New Medical Technologies]. 2014; 21 (1): 36-8. (in Russian)

10. Szosland D. Shift work and metabolic syndrome, diabetes mellitus and ischaemic heart disease. Int J Occup Med Environ Health. 2010; 23 (3): 287-91.

11. Voznesenskaya T.G. eating Disorders in obesity and their correction. Ozhirenie i metabolism [Obesity and Metabolism]. 2004; 1 (2): 2-6. (in Russian)

12. Chen K.Y., Brychta R.J., Abdul Sater Z., Cassimatis T.M., Cero C., Fletcher L.A., et al. Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity. J Biol Chem. 2020; 295 (7): 1926-42. DOI: 10.1074/jbc. REV119.007363

13. Ametov A.S. The Obesity. Modern view on pathogenesis and therapy: Textbook. Moscow: GEOTAR-Media, 2019; (I): 384 p. (in Russian)

14. Romantsova T.I. Sibutramin: effectiveness and safety of prescribing in routine clinical practice. Ozhirenie i metabolism [Obesity and Metabolism]. 2015; 12 (3): 18-24. (in Russian)

15. Ametov A.S., P’yanykh O.P., Nevol’nikova A.O. Modern opportunities of metabolic health management in patients with obesity and carbohydrate metabolism disorders. Endokrinologiya: novosti, mneniya, obu-chenie [Endocrinology: News, Opinions, Training]. 2020; 9 (1): 17-26. DOI: 10.33029/2304-9529-2020-9-1-17-26. (in Russian)

16. Romantsova T.I., Sych Yu.P. Immunometabolism and meta-inflammation in obesity. Ozhirenie i metabolism [Obesity and Metabolism]. 2019; 16 (4): 3-17. (in Russian)

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)